There are several Frontrunners League Members (game-changers who have been featured in The Introducer Magazine) who have been developing and finetuning their diabetes innovations. Since they have been featured in the magazine, many have made significant gains in the space, and we wanted to share with you their updates and who they need to connect with to continue that impact. If you have a business interest in meeting any of them, please connect with the League’s Communication Dir., at email@example.com
Joe is the CEO of GoX Labs.
Wearable to Predict Diabetes Conditions: GoX is in partnership with Microsoft, AT & T, and Samsung on this project.
GoX is a wholly-owned subsidiary of GoX Studio, Inc. Workforce injury prediction enabled by IoT wearables and AI delivered via SaaS platform. Strong traction with Fortune 500 companies in multiple industries including insurance, ergonomics and corporate wellness. Customers in the US and EU.
As of early October 2019, GoX launched simultaneous diabetes prevention pilots their wearable watch in California and Arizona. Working with hospitals in both states, GoX hopes to demonstrate significant HbA1c reduction and HbA1c prediction without a blood sample. Dr. Joe Hitt, GoX Lab’s CEO, “This is the first known study where the HbA1c diagnostic is without breaking the skin and the therapy is only 30 minutes of moderate-intensity walking per day regulated jointly by the participant, coach, and provider.”
We predict your future diabetes using the data we collect from a smartwatch and artificial intelligence. No blood draws, weight scales, fad diets or hours at the gym. We just need a commitment of 2.5 hours per week to a healthier you.
●Chat with a health professional weekly to go over goals
●Tracks VO2, HRX, steps, speed, sleep, and nutrition
●Machine learning provides diabetes (HbA1c) prediction
●Rewards program from social to financial
●High level of encryption security, no personally identifiable information collected
GoX Labs has created a smarter mobile solution that averages 11.7 times greater accuracy than the leading consumer fitness trackers (Fitbit , Garmin, and others ) for calories burned in independent tests.
Joe’s Networking Interest: Contacts in Insurance, Rehabilitation Hospitals, and Telemedicine interested in a demo for potential collaboration for trials.
AI Conversation Chatbot as a Wellness Educator and Coach:
Mei and her partner, Michel Decary, founders of Cogilex R & D, Inc. and SEENSO Health have developed an AI Conversational Chatbot to help patients with diabetes self-manage their disease with the best information accessible on demand. Below is a 10-minute video that includes a demo of a conversation between Michel and Nurse Gordon (the chatbot.) Cogilex was recently selected as one of eight to pitch at AI Med Shark Tank, Australia.
We had our Youth Editor, Marley Dozier, (see an update on Marley’s own medical adventure below) try out Nurse Gordon, the chatbot, and afterward, send Mei some questions. We’re sharing her questions and Mei’s responses below:
Question: Will Nurse Gordon be accessible to the public or just patients?
Answer: “Nurse Gordon can be used by both patients and the general public. However, as it involves a significant operational cost, we will need to find a way to compensate such cost by subscriptions or institutional contracts.”
Question: In the event of an emergency, while waiting for rescue services to arrive, could Nurse Gordon walk you through life-saving techniques?
Answer: Although Nurse Gordon can offer a set of information about what to do in an emergency situation, at this moment, it does not walk the user through step-by-step instruction. This will be a feature as the development progresses.
Question: As Nurse Gordon converses, could he become fluent in speech with humans or are his responses programmed according to key words he hears in a question?”
Answer: A voice assistant is a popular form of AI voice technology that uses voice recognition, text-to-speech, and natural-language
In addition to these features, Cogilex’s chatbot has a dynamic dialogue management system that is capable of multi-turn natural conversations using clues picked up from the ongoing conversations. It involves natural language understanding, knowledge representation, user modeling, conversation management, and other techniques.
Mei’s Networking Interest: Contacts at Pharmaceutical companies, Clinics, and Insurance companies who are exploring new methods to serve patients’ healthcare needs.
Marley Dozier is our Youth Editor for The Introducer Magazine and has an interest in medicine as a career. In the summer of 2019, Marley took part in a leadership camp at Johns Hopkins University (featured in Edition # 12, The Real Value of Health Tech). Marley shares her adventure at Johns Hopkins here:
In Marley’s words…“You are Atlas. The world will be balanced on your shoulders,” said, Dr. James Giordano. What he said to us I will never forget. During my experience at Johns Hopkins, we had different lectures, one of which was from Dr. Giordano, Ph.D., Chief, Neuroethics Studies Prog, Georgetown UMC. The reasons I loved the medical field all fell into the light as I sat there listening to his lecture. I stayed on campus from July 14 through 23, 2019. When I was offered this amazing opportunity, I just had to go for it. At that point, I knew I had a passion for medicine and I just could not wait to get my geek on! The experiences I received were incredible! I was able to have hands-on experience with some of the most prestigious, cutting-edge technology that is used in the medical field and what medical students use to learn! I was also able to ask questions about college, medical school, and, any questions I had were answered by surgeons, physicians, researchers, and even medical students. An amazing opportunity.”
Wearable Biosensor: Update from Todd: On September 25, 2019, autonomous_ID Inc., a wholly-owned subsidiary of autonomous_ID Corporation was awarded an NIH/NIAAA research project in partnership with Sugpiat Defense Group, a wholly-owned subsidiary of our Alaskan Native Corporation partner, Akhiok-Kaguyak Inc., using Bio_Sole as a Wearable Biosensor that Quantifies Blood Alcohol Concentration in Real-Time.
We are very pleased that the NIH researchers have acknowledged the merits of our “feet first” approach to identifying gait-related biomarkers. This awarded project represents one of many programs pending across a broad range of disease phenotypes, sickness, and injury with known gait and balance-related abnormalities.
In further applying Bio_Sole native diagnostic capabilities, there is an ability to incorporate measures of blood alcohol level and bodily changes associated with blood sugar, blood pressure, body temperature, and symptoms of alcohol withdrawal. This technology also has the potential for detecting health and safety concerns for Diabetic episodes. The pressure and thermal sensors are helpful in detecting a foot ulcer and the heat sensor can detect a rising temperature which can be attributed to a sign of infection.
Tony Robinson, our long-standing CISO has been promoted to corporate CTO and Gregg McNulty, former SVP & CTO at CVS with a respected history at Avaya, eBay Enterprises, Merck, Medco Health Solutions, and Johnson & Johnson has joined the company as corporate CIO. With Dr. Grisoni, former Principle Scientist (Merck/Dr. Scholl) leading autonomous Manufacturing and Supply, we benefit greatly with world-leading expertise building the next generation of smart footwear.
As we move forward to bring our platform and analytical services to market, we welcome the energy, drive, and ambitions of Tony, Gregg, and the many others who have joined the autonomous journey these past months. While the norm is getting the product on the shelf quick and dirty, we strive to do it right the first time, and without compromise.
Todd’s Networking Interest: Hospital administrators
Steven Reid is a Frontrunners League Member in R & D on a glucose monitoring solution.
Steven’s background is in Mechanical Engineering and IT. His interest lies in new technologies that can help support diabetics in the management of their condition. He is conducting research and development into a non-invasive continuous blood glucose monitoring solution.
Based in Scotland, Steven has been a Type 1 Diabetic for 19 years and is currently using the Loop, Do-It-Yourself, artificial pancreas software developed by the #WeAreNotWaiting community to automate and manage the delivery of his insulin.
Steven’s Networking Interest: universities, institutions or accelerators who could, at a lower cost, help with rapid development of a prototype.
GIOSTAR Engaged with USA FDA to Carry 0ut Stem Cells-Based Clinical Trial for Diabetes Type 2
by Deven, President, CEO, & Co-Founder, Global Institute of Stem Cell Therapy and Research (GIOSTAR)
Diabetes is increasing at a rampant rate all around the globe which is affecting developed countries more severely than developing ones. In the USA itself, almost 10% of the population has been living with diagnosed or undiagnosed diabetes. Since such a big section of the population is affected by diabetes, the cost of taking care of the individuals is also increasing. According to an assessment by the Diabetes Association of America, the cost of taking care of diabetics had added up to $327 billion in 2017. Out of which $237 billion was direct medical cost and remaining because of reduced productivity. Type II diabetes, which is caused by loss of insulin sensitivity is seen more commonly in the older population. However, with increasing easy and unimpeded availability of high-calorie foods and decreasing factors necessitating physical work, it is showing up in the younger population significantly. About 193,000 Americans under the age of 20 years are estimated to have diagnosed diabetes.
Though a number of medications are already in clinical use, none of them grant a long-term cure and all of them have some or other undesired side effects. To circumvent all these concerns another alternative way of handling the problem was needed for a long time. Discovery of stem cells and related extensive research has offered a ray of hope to manage the problem efficiently with a sound possibility of a permanent cure. Stem cells, depending on the source of their origin or due to post-isolation manipulations, are classified as embryonic or adult or induced.
Keeping different facts in a view, GIOSTAR Chairman, Dr. Anand Srivastava, started his research to differentiate stem cells into the insulin-secreting cells, which may be used for therapeutic purposes. Therefore, GIOSTAR is in the process of USA-FDA approval for a clinical trial to develop a stem cell-based treatment for Diabetes type 2.
Mesenchymal stem cells (MSCs), isolated from visceral fatty tissues of adults, are known to promote the regeneration of pancreatic islet beta cells, protect them from apoptosis, and ameliorate insulin resistance in peripheral tissues by providing a supportive niche microenvironment driven by the secretion of paracrine factors or the deposition of the extracellular matrix. In general, implantation of MSCs can alleviate T2D by a number of mechanisms that include reducing systemic oxidative stress, a factor responsible for causing the death of insulin-producing cells and at the same time, contributing to insulin resistance too. Also, these cells, after being exposed to pro-inflammatory cytokines like IFN-g, become a source of anti-inflammatory cytokines. These cells, if implanted directly in the pancreas, due to their multipotential ability to differentiate in diverse types of cells of their immediate vicinity, can produce new insulin-producing cells. To promote the chances of their differentiation into insulin-producing cells, their preprogramming has been tried. Also, intravenous infusion of stem cells has been shown to regenerate beta cells of pancreatic islets and promote insulin sensitivity by decreasing systemic inflammation, the root cause of insulin resistance.
Encouraging findings in cases of diabetes treatments with stem cell therapies have led many clinicians to try implantation or infusion or both in the clinics. In more than 150 trials at different stages listed on NIH’s webpage implantation or infusion of MSCs have shown promising results up to several months of follow up. A couple of clinical parameters like H1Ac and needed insulin to manage blood glucose decreased after the MSC-treatments, which was also accompanied by increased insulin sensitivity.
Stem cell therapy may have some undesirable effects, though the incidences are few and far between. Even those undesired effects like mild to moderate fever or nausea or headache, which happen after stem cell transplantation, are very mild and are easily manageable.
In conclusion, GIOSTAR Chairman Dr. Anand Srivastava stated that stem cell therapy may offer a long-lasting therapeutic alternative for treating T2D. At the same time, it has to be kept in mind that it is not a permanent cure yet. T2D is a metabolic syndrome manifesting after a long duration of an unhealthy lifestyle that needs to be addressed in order to lead a healthy life. Compared to all other available therapies, stem cell therapy may offer a lot longer drug-free periods for individuals to develop a healthy lifestyle in order to fend off the re-occurrence of the disease.
Deven’s Networking Interest: Hospitals and clinics interested in partnering for clinical trials.